Shall we cycle TNFi in AxSpA? CorEvitas registry 86 pts 70% TNFi monotherapy, 23% NSAIDs, 42% high & 24% v high DA Cycling to 2nd line TNFi At 6 months: very low achievement of ASDAS-LDA (15%), MCID in ASDAS (7%) & no MI. https://t.co/S9vnz5PXuX Abs#1499 #ACR22 @Rheumnow https://t.co/1IZIYcPCBz

Pan et al 11beta-hydroxysteroid dehydrogenase inhibitor SPI-62 mitigates glucocorticoid toxicity in mouse model. Human trial in PMR ongoing. @RheumNow #ACR22 Abstr#1549 https://t.co/t74Hazll9H https://t.co/4425RUwIz4

Mepolizumab assoc'd w/ clinical benefits in EGPA, including in patients w/ and w/o a vasculitic phenotype. Abs 1074 #ACR22 @RheumNow https://t.co/VCGhGaci8b https://t.co/OV8A1vsx1G

Filho et al. Retrospective Brazilian study. ADA vs LEF in Takayasu arteritis. Comparable renission, relapses, steroid dose, ESR, CRP, imaging over median 15 weeks. More AEs in LEF but non-severe. @RheumNow #ACR22 Abstr#1553 https://t.co/499dUNmpUD https://t.co/AEk5cG7dc4

Juge @Juge_P_A @PhilippeDieude et al. RA-ILD patients have shorter telomere length than RA without ILD. RA-ILD similar telomere length to IPF. OR 0.54 for RA-ILD. Assoc with FVC%pred also. @RheumNow #ACR22 Abstr#1122 https://t.co/H5A7unpjjB https://t.co/IjvHmupykM

Del-Río-Guerrero et al. Sphygmomanometry-induced allodynia for fibromyalgia detection. 62% sensitivity and 84% specificity. Much pain = 23% sensitivity and 96% specificity. Only seems to apply in female patients. @RheumNow #ACR22 Abstr#1225 https://t.co/zCHfmvwOcn https://t.co/tjBBny0WSR

Abstr 1255 Do Rheumatologists overcall sacroiliitis on imaging in axSpA? Compared to central readers: -Agreement w/ local readers = 87% agreement (X-Rays); 74.5% (MRIs) - Agreement w/ Academic rheumatologists was greater vs community rheumatologists #ACR22 @RheumNow https://t.co/j2vFoKA3n0

Study by Dr EPapachristodoulou on features of #lupus pts w/ LAD: myo/pericarditis, cytopenias, nephritis,⬆️markers Those w/LN biopsy: reactive(66.7%) vs. necrotizing(33.3%) pattern 👉Pts w/ necrotizing pattern: unexplained fevers, sicca& malar rash. #ACR22 @RheumNow ABST1443 https://t.co/J4aMRnYk8N

Avacopan's efficacy and safety profiles support use in AAV in Abs 1077 #ACR22 @RheumNow https://t.co/Zp05ofTgFP https://t.co/zA2sIEfYCS

Join us for our daily topic panels--we'll be live on Twitter, LinkedIn, FB and YouTube OR sign up directly below. #ACR22 https://t.co/Oql4iv6RyO https://t.co/S4t7ucliUF

Much gusto for GUSTO: Efficacy of Tocilizumab Monotherapy for GCA Dr. Richard Conway discusses abstract 0470 - being presented at the #ACR22 meeting. https://t.co/btztbYWjq1 https://t.co/hrpZhIRLKO

Ab1115 #ACR22 Rx Co-Pay affects Rx Adherence in SLE Higher copays associated w/: 💊39% lower odds of HCQ adherence 💊56% lower AZA adherence 💊32% lower MMF adherence Need better $$ and transparency into costs. Screen for determinants of health affecting affordability! @Rheumnow https://t.co/1NdBb3GLzL